Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DRMA 
Dermata Therapeutics Inc (DRMA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/14/2025: DRMA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.96% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.14M USD | Price to earnings Ratio 0.15 | 1Y Target Price 10 |
Price to earnings Ratio 0.15 | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 0.53 | 52 Weeks Range 2.90 - 16.50 | Updated Date 11/15/2025 |
52 Weeks Range 2.90 - 16.50 | Updated Date 11/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 20.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -110.91% | Return on Equity (TTM) -231.27% |
Valuation
Trailing PE 0.15 | Forward PE - | Enterprise Value -4342818 | Price to Sales(TTM) - |
Enterprise Value -4342818 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.58 | Shares Outstanding 681557 | Shares Floating 498470 |
Shares Outstanding 681557 | Shares Floating 498470 | ||
Percent Insiders 17 | Percent Institutions 7.02 |
Upturn AI SWOT
Dermata Therapeutics Inc
Company Overview
History and Background
Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on identifying, developing, and commercializing innovative, differentiated, and proprietary product candidates for the treatment of medical skin diseases. Founded in 2014, it went public in 2021. Its initial focus was on dermatology issues and has since shifted to indications such as rosacea, acne, and hyperhidrosis.
Core Business Areas
- Dermatology Product Development: Focused on developing and commercializing treatments for dermatological conditions.
Leadership and Structure
Details about the leadership team and structure are generally found on the company's investor relations website, including executive officers and board members. The company follows a standard corporate structure with a CEO, CFO, and other key leadership positions overseeing various departments such as research and development, clinical operations, and commercial strategy.
Top Products and Market Share
Key Offerings
- DRM02: DRM02 is a Spironolactone based topical treatment for acne and rosacea. Phase 3 trials are underway. Competitors include generic topical treatments, other prescription topicals, and oral medications for acne and rosacea. Market share data is not yet applicable as the product is not yet commercialized.
- DRM04: DRM04 is a once-daily topical treatment for hyperhidrosis, a condition characterized by excessive sweating. Phase 2b trials are underway. Competitors include Drysol, Qbrexza, Botox injections, and miraDry. Market share data is not yet applicable as the product is not yet commercialized.
Market Dynamics
Industry Overview
The dermatology market is characterized by high demand for treatments for common skin conditions like acne, rosacea, eczema, and psoriasis. The industry is driven by innovation in topical and systemic therapies, as well as growing awareness and acceptance of cosmetic procedures.
Positioning
Dermata is positioning itself as an innovator in topical dermatology, aiming to develop differentiated products with improved efficacy and safety profiles compared to existing treatments. Its competitive advantage lies in its proprietary formulations and targeted approach to specific skin conditions.
Total Addressable Market (TAM)
The global dermatology market is expected to reach hundreds of billions of dollars. Dermata is focusing on specific segments within this market, such as acne, rosacea, and hyperhidrosis, with potentially significant TAMs. Dermata is positioned to capture a portion of these TAMs with successful product launches.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technology
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Lack of commercial infrastructure
Opportunities
- Growing dermatology market
- Unmet needs in specific skin conditions
- Potential for partnerships and acquisitions
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- VRX
- BHC
- ALNY
- LEO
Competitive Landscape
Dermata competes with large pharmaceutical companies and smaller biotech firms developing treatments for dermatological conditions. Its advantages include its proprietary technology and focus on specific niche markets. Its disadvantages include limited resources and the risk of clinical trial failures.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as a clinical-stage company. Growth will be measured by progress in clinical trials and achievement of milestones.
Future Projections: Future projections depend on successful clinical trials, regulatory approvals, and commercialization of its product candidates. Analyst estimates are needed for specific projections.
Recent Initiatives: Recent strategic initiatives include advancing DRM02 and DRM04 through clinical trials, presenting clinical data at scientific conferences, and securing additional funding.
Summary
Dermata Therapeutics is a clinical-stage biotechnology company with promising product candidates targeting specific dermatology markets. Its success hinges on positive clinical trial results and securing adequate funding. While it faces competition from established players, its proprietary technology could provide a competitive edge. Investors should monitor clinical trial progress and financial performance closely. Clinical trial failures and market competition pose significant risks.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Dermata Therapeutics Inc. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Information is based on publicly available data and is subject to change. The AI-based rating is based on an algorithm and is not a guarantee of future performance. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dermata Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-08-13 | Founder, President, CEO & Chairman Mr. Gerald T. Proehl | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.dermatarx.com |
Full time employees 8 | Website https://www.dermatarx.com | ||
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.